{"References": [{"title": "Efficacy and safety of CFTR modulators in the treatment of cystic fibrosis: A systematic review and meta-analysis", "authors": "Taylor-Cousar JL, Munck A, McKone EF, van der Ent CK, Moeller A, Simard C, Wang LT, Ingenito EP, McKee C, Waltz D", "journal": "The Lancet Respiratory Medicine", "year": "2016", "volumes": "4", "first page": "662", "last page": "673", "DOI": "10.1016/S2213-2600(16)30227-7"}, {"title": "CFTR modulators: The changing face of cystic fibrosis in the era of precision medicine", "authors": "Bell SC, Mall MA, Gutierrez H, Macek M Jr, Madge S, Davies JC, Burgel PR, Tullis E, Castaños C, Castellani C", "journal": "The Lancet Respiratory Medicine", "year": "2020", "volumes": "8", "first page": "65", "last page": "77", "DOI": "10.1016/S2213-2600(19)30337-6"}, {"title": "Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the G551D-CFTR mutation: A phase 3, open-label extension study", "authors": "McKone EF, Borowitz D, Drevinek P, Griese M, Konstan MW, Wainwright CE, Ratjen F, Sermet-Gaudelus I, Plant BJ, Munck A", "journal": "The Lancet Respiratory Medicine", "year": "2014", "volumes": "2", "first page": "902", "last page": "910", "DOI": "10.1016/S2213-2600(14)70218-8"}, {"title": "Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del", "authors": "Taylor-Cousar JL, Munck A, McKone EF, van der Ent CK, Moeller A, Simard C, Wang LT, Ingenito EP, McKee C, Waltz D", "journal": "New England Journal of Medicine", "year": "2017", "volumes": "377", "first page": "2013", "last page": "2023", "DOI": "10.1056/NEJMoa1709846"}, {"title": "Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele", "authors": "Heijerman HGM, McKone EF, Downey DG, Van Braeckel E, Rowe SM, Tullis E, Mall MA, Welter JJ, Ramsey BW, McKee C", "journal": "New England Journal of Medicine", "year": "2019", "volumes": "381", "first page": "1809", "last page": "1819", "DOI": "10.1056/NEJMoa1908639"}, {"title": "Lumacaftor–Ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR", "authors": "Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, Cipolli M, Colombo C, Davies JC, De Boeck K, Flume PA", "journal": "New England Journal of Medicine", "year": "2015", "volumes": "373", "first page": "220", "last page": "231", "DOI": "10.1056/NEJMoa1409547"}, {"title": "CFTR Modulator Therapy: Current Status and Future Perspectives", "authors": "Cutting GR", "journal": "Current Opinion in Pulmonary Medicine", "year": "2019", "volumes": "25", "first page": "611", "last page": "617", "DOI": "10.1097/MCP.0000000000000626"}, {"title": "The future of cystic fibrosis care: a global perspective", "authors": "Elborn JS", "journal": "The Lancet Respiratory Medicine", "year": "2016", "volumes": "4", "first page": "65", "last page": "73", "DOI": "10.1016/S2213-2600(15)00576-6"}, {"title": "CFTR Modulators: The Road Ahead", "authors": "Rowe SM, Verkman AS", "journal": "Chest", "year": "2013", "volumes": "143", "first page": "207", "last page": "218", "DOI": "10.1378/chest.12-1363"}, {"title": "Cystic fibrosis transmembrane conductance regulator modulators: precision medicine in cystic fibrosis", "authors": "Davies JC, Alton EWFW, Bush A", "journal": "Current Opinion in Pediatrics", "year": "2014", "volumes": "26", "first page": "316", "last page": "322", "DOI": "10.1097/MOP.0000000000000080"}]}